CODEN [USA]: IAJPBB ISSN: 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

http://doi.org/10.5281/zenodo.1048230

Available online at: http://www.iajps.com *Review Article*

TARGETING HIF-1 PATHWAY: A THERAPEUTIC APPROACH TO KILL CANCER CELLS

Ajaz Ahmad Waza[1*], Shabir Ahmad Bhat[1], Zeenat Hamid[2]

[1]Centre of research for development (CORD) University of Kashmir, Srinagar, Jammu and Kashmir, 190006, India. ajazahmad09@gmail.com, bhatshabir2007@gmail.com
[2]Department of Biotechnology, University of Kashmir, Srinagar, Jammu and Kashmir, (190006) India. zeenathmd269@gmail.com

Abstract:
Tumorous growth often faces hypoxic (low oxygen tension) conditions and the adaptations of these cells to hypoxic conditions determine their survival. The cancer cells respond to hypoxia by altering the expression of different genes and Hypoxia-Inducible Factor (HIF)-1 is one of it. HIF-1 is a transcriptional factor that response to hypoxia (low oxygen tension) conditions quickly. Expression of HIF-1 gene is essential for increase in vascularization of hypoxic region such as tumor and thus aid in proliferation and survival of cancerous cells. Moreover, HIF-1 signaling in cancer cells has a diverse influence on the metastatic cascade. Targeting HIF-1 is therefore one of the most promising approach to treat cancer. In this review, we have focused on the potential of targeting HIF-1 pathway as therapeutic intervention to treat cancer.

Key words: HIF-1 Pathway, Cancer, *Hypoxia-Inducible*

***Corresponding author:**
Ajaz Ahmad Waza,
Centre of research for development (CORD),
University of Kashmir, Srinagar, Jammu and Kashmir,
190006, India.
E-Mail:ajazahmad09@gmail.com, bhatshabir2007@gmail.com

QR code

Please cite this article in press as Ajaz Ahmad Waza et al., ***Targeting Hif-1 Pathway: A Therapeutic Approach to Kill Cancer Cells****, Indo Am. J. P. Sci, 2017; 4(11).*

INTRODUCTION:

Hypoxia is the deficiency either in the delivery or the utilization of oxygen at the cellular level, which can alter various physiological functions of the cells, with severe consequences to the organism. In humans, the hypoxic conditions occur during various pathophysiological conditions, like tumorous growth, myocardial ischemia, stroke etc [1] [2] [3]. When cells sense a decrease hypoxia, they develop adaptive responses in order to sustain this condition and survive. If hypoxia lasts too long or is too severe, the cells eventually die [4]. Interestingly, tumorous growths often face hypoxic conditions and the adaptations of these cells to hypoxic conditions determine the prognostic potential of the tumors. Indeed, it has also been shown that hypoxia contributes to the selection of cells with decreased apoptotic potential and high metastatic capability [5]. The cells respond to hypoxia by altering the expression of various genes and most important one is HIF-1 [6].

One of the important signaling pathways activated during hypoxia conditions in cancer cells is HIF-1 signaling. HIF-1 is a heterodimeric consists of α-subunit (oxygen-regulated) and β-subunit (constitutively expressed). The HIF-1α subunit is oxygen sensitive due to the presence of an oxygen-dependent degradation (ODD) domain. Under normal conditions, prolyl hydroxylases hydroxylate HIF-1 α subunit at proline residues and triggers their proteasomal degradation [7] [8] [9] [10]. But under hypoxia conditions, HIF-α is stabilizes and translocated to nucleus, as prolyl hydroxylases are inhibited. Within nucleus HIF-α dimerize and bind to hypoxia-responsive elements (HREs) of allow their expression. It should be noted here that HIF-1 allows expression of 100s of genes and thus boost cellular capacity to survive in hypoxia environment (see figure 1). The microenvironment around the tumorous area is highly hypoxic, but activation of HIF-1 allows proliferation of such tumors by enhancing angiogenesis. Increased angiogenesis increases oxygen supply to the cancerous area and therefore promote their growth [11] [12]. So based on its central role in survival of cancer cells, manipulation of HIF-1 activity in tumor masses has emerged as a focus now-a-days to develop pharmaceutical and noninvasive treatment, as an alternate options for cancer patients.



Fig. 1: Shows activation of HIF-1 pathway: During hypoxia stress, HIF1-α gets stabilize and is tranlocated to nucleus, where it dimerizes with HIF1-ß to form a complex. The dimer recognizes the HREs on the target genes and allows their expression.

Table 1: Human cancers exhibiting increased levels of HIF-1 protein.

Cancer type	References
Bladder cancer	**[13]**
Breast	[14]
Cervical cancer	[15]
Colon cancer	[16]
Colorectal cancer	[17]
Endometrial cancer	[18]
Esophageal Squamous cell carcinoma (SCC)	[19]
Gastrointestinal stromal tumor	[20]
Glioma	[21]
Head and neck SCC	[22]
Laryngeal cancer	[23]
Liver cancer	[24]
Lung cancer	[25]
Melanoma	[26]
Oligodendroglioma	[27]
Ovarian cancer	[28]
Prostate cancer	[29]
Renal cancer	[30]

Proper oxygen (O_2) supply is required by the mammalian cells to grow, proliferate and to maintain aerobic metabolism properly. However in tumor cells O_2 supply is impaired due to decrease in O_2 delivery and diffusion and therefore hypoxic condition is created. Hypoxia is considered as a prominent characteristic feature in the tumor tissue which drives aggressiveness of a tumor mass [31]. It should be noted here that the cancer cells counter this hypoxia conditions by activating HIF-1 pathway, which inturn modify the cellular environment to combat the hypoxic stress condition. HIF-1 plays a central role in hypoxia and is therefore considered to be an essential protein in tumor proliferation [32]. The expression level of HIF-1 is increased in different tumor tissues and positively correlates with tumor aggressiveness and poor prognosis (see table 1). To further support the role of HIF -1 in cancer progression, it has been found that loss of HIF-1α function is associated with the decrease in tumor growth, vascularization, and metastasis.

As earlier stated, HIF-1 activation is responsible for the tumor progression, and therefore inhibiting its activation could be used as a therapeutic approach in cancer. However, the HIF-1 pathway is a highly complex mechanism and involves activation of a diverse proteins, each of which may serve target to in an anti cancer therapy approach [33]. Down regulation of HIF-1 protein is considered to be the main strategy that could be attained via activation of hydroxylases. Actually such hydroxylases belong to the 2-oxoglutarate (2OG)-dependent oxygenase superfamily and require a ferrous ion, as a cofactor for activation. Treatment of cells with iron and ascorbate has been found to decline HIF-1 protein levels and its target genes [34]. Till date, many types of HIF-1 inhibitors have been discovered and some are under clinical trials. Each inhibitor act via a specific mode of action to manipulate HIF-1 pathway and some of the inhibitors are mentioned here. Echinomycin, nutlin-3 and bortezomib inhibit the HIF-1-mediated gene expressions [35] [36] [37]. Microtubule disruptors, HSP90 inhibitors, and YC-1 destabilize HIF-1α in the post-translational level [38] [39] [40]. Some other agents such as topotecan, digoxin, PX-478, rapamycin and chaetocin block de novo synthesis of HIF-1α protein [41] [42] [43] [44] [45]. Similarly HIF-1α inhibition by using siRNA *in vivo* and *in vitro* has been reported to decreased growth and metastasis of cancerous cells [46] [47] [48]. More and more understanding of the HIF-1 domains like their structure and molecular biology will result in unearthing therapeutic molecules.

CONCLUSION:

Hypoxia is a well known phenomenon in solid tumor masses due to insufficient vascularization. Cancer cells activate HIF-1 pathway to deal with this O_2 stress, which inturn support a vast number of cellular processes. As HIF-1 protein has a well known role in supporting growth and proliferation of cancerous cells and therefore its targeting has emerged an alternate way to deal with the tumor growth. It should be noted here that till date no specific HIF-1α inhibitor has been approved clinically, although different anti cancer drugs are in use that indirectly affect the HIF-1 pathway. Due to its central role in supporting growth and metastasis of tumor cell, it is

promising that in near future specific HIF-1α inhibitors will be developed and clinically approved.

ACKNOWLEDGEMENTS:
Council of Scientific & Industrial Research (CSIR) and The Science & Engineering Research Board (SERB) GOI, New Delhi are acknowledged for providing fellowship to Ajaz Ahmad Waza (CSIR-RA fellow, No. 9/251 (0077) / 2k17) and Shabir Ahmad Bhat (PDF/2016/003730) respectively.

REFERENCES:

1.Muz, B., et al., The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia, 2015;3: p. 83-92.
2.Chi, N.C. and J.S. Karliner, Molecular determinants of responses to myocardial ischemia/reperfusion injury: focus on hypoxia-inducible and heat shock factors. Cardiovascular research, 2004; 61(3): p. 437-47.
3.Ferdinand, P. and C. Roffe, Hypoxia after stroke: a review of experimental and clinical evidence. Experimental & translational stroke medicine, 2016; 8: p. 9.
4.Lenihan, C.R. and C.T. Taylor, The impact of hypoxia on cell death pathways. Biochemical Society transactions, 2013;41(2): p. 657-63.
5.Rankin, E.B. and A.J. Giaccia, Hypoxic control of metastasis. Science, 2016;352(6282): p. 175-80.
6.Ziello, J.E., I.S. Jovin, and Y. Huang, Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. The Yale journal of biology and medicine, 2007; 80(2): p. 51-60.
7.Epstein AC, G.J., McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ., C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell., 2001; 107(1): p. 43-54.
8.Bruick RK, M.S., A conserved family of prolyl-4-hydroxylases that modify HIF. Science., 2001; 294: p. 1337-1340.
9.Jaakkola, P., et al., Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science, 2001; 292(5516): p. 468-72.
10.Ivan, M., et al., HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science, 2001; 292(5516): p. 464-8.
11.Carmeliet P, D.Y., Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E., Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. . Nature, 1998; 394: p. 485-90.
12.Laderoute KR, A.K., Calaoagan JM, Knapp M, Le T, Orduna J, Foretz M, Viollet B, 5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumormicroenvironments. Mol Cell Biol, 2006;26: p. 5336-47.
13.Huang, Z., et al., A chronic obstructive pulmonary disease negatively influences the prognosis of patients with bladder urothelial carcinoma via hypoxia inducible factor-1alpha. International journal of clinical and experimental medicine, 2014; 7(10): p. 3344-53.
14.Maroni P, M.E., Drago L, Banfi G , Bendinelli P, Desiderio MA Hypoxia induced E-cadherin regulators of Hippo pathway due to HIF-1a stabilization/nuclear translocation in bone metastasis from breast carcinoma. . Exp Cell Res., 2015; 330: p. 287-299.
15.Haugland HK, V.V., Pintilie M, Fyles AW, Milosevic M, Hill RP, Hedley DW., Expression of hypoxiainducible factor-1a in cervical carcinomas: correlation with tumor oxygenation. . Int J Radiat Oncol Biol Phys., 2002; 53: p. 854-861.
16.Jo JO, K.S., Bae MK, et al. , Thymosin b4 induces the expression of vascular endothelial growth factor (VEGF) in a hypoxi ainducible factor (HIF)-1a-dependent manner. . BBA-Mol Cell Res., 2010; 1803: p. 1244-1251.
17.Malfettone, A., et al., Overexpression of nuclear NHERF1 in advanced colorectal cancer: association with hypoxic microenvironment and tumor invasive phenotype. Experimental and molecular pathology, 2012; 92(3): p. 296-303.
18.Horree N, G.E., Van der Groep P, Heintz AP, Vooijs M, van Diest PJ., Hypoxia-inducible factor1a is essential for hypoxic p27 induction in endometrioid endometrial carcinoma. . J Pathol., 2008; 214: p. 38-45.
19.Chen Y, L.Y., Lu C, Zhang L. , Beclin-1 expression is a predictor of clinical outcome in patients with esophageal squamous cell carcinoma and correlated to hypoxia-inducible factor (HIF)-1a expression. Pathol Oncol Res., 2009; 15: p. 487-493.
20.Takahashi R, T.S., Hiyama T, Ito M, Kitadai Y, Sumii M, Haruma K, Chayama K., Hypoxia-inducible factor 1a expression and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncol Rep, 2003; 10: p. 797-802.
21.Hermansen SK, N.B., Aaberg-Jessen C, Kristensen BW., miR-21 is linked to glioma angiogenesis-a co-localization study. J Histochem Cytochem., 2016;64: p. 138-148.

22.Jokilehto T, R.K., Luukkaa M, Heikkinen P, Grenman R, Minn H, Kronqvist P, Jaakkola PM., Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness. Clin Cancer Res, 2006; 12: p. 1080-1087.
23.XIAO-HONG WU, S.-P.C.J.-Y.M., XUE-XIAN JI, HONG-TIAN YAO, and SHUI-HONG ZHOU, Expression of hypoxia inducible factor-1a and its significance in laryngeal carcinoma. J Int Med Res, 2010;38: p. 2040-2046.
24.Yasuda, S., et al., Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 alpha and its significance. Journal of hepatology, 2004; 40(1): p. 117-23.
25.Arnoldo Aquino-Gálvez, G.G.-Á., Javier Delgado-Tello, Manuel Castillejos-López, Criselda Mendoza-Milla, Joaquín Zúñiga, Marco Checa, Héctor Aquiles Maldonado-Martínez, Axel Trinidad-López, José Cisneros, Luz María Torres-Espíndola, Claudia Hernández-Jiménez, Bettina Sommer, Carlos Cabello-Gutiérrez, And Luis H. Gutiérrez-González. Effects of 2-methoxyestradiol on apoptosis and HIF-1a and HIF-2a expression in lung cancer cells under normoxia and hypoxia. Oncol Rep., 2016; 35: p. 577-583.
26.Slominski A, K.T., Brozyna AA, Janjetovic Z, Brooks DL, Schwab LP, Skobowiat C, Jóźwicki W, Seagroves TN., The role of melanogenesis in regulation of melanoma behavior: Melanogenesis leads to stimulation of HIF-1a expression and HIF-dependent attendant pathways. . Arch Biochem Biophys., 2014; 563: p. 79-93.
27.Abraham, S., N. Hu, and R. Jensen, Hypoxia-inducible factor-1-regulated protein expression and oligodendroglioma patient outcome: comparison with established biomarkers and preoperative UCSF low-grade scoring system. Journal of neuro-oncology, 2012; 108(3): p. 459-68.
28.Zhou ZL, L.Z., Yu B, Jiang Y, Chen Y, Feng JM, Dai M, Tong LJ, Li Z, Li YC, Ding J, Miao ZH., Increased accumulation of hypoxiainducible factor-1a with reduced transcriptional activity mediates the antitumor effect of triptolide. . Mol Cancer, 2010;9: p. 268-278.
29.Zapatero, A., et al., HIF1A expression in localized prostate cancer treated with dose escalation radiation therapy. Cancer biomarkers : section A of Disease markers, 2015; 15(1): p. 41-6.
30.Klatte T, S.D., Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS., Hypoxia-inducible factor 1a in clear cell renal cell carcinoma. . Clin Cancer Res., 2007; 13: p. 7388–7393.
31.Vaupel, P. and A. Mayer, Hypoxia in tumors: pathogenesis-related classification, characterization of hypoxia subtypes, and associated biological and clinical implications. Advances in experimental medicine and biology, 2014; 812: p. 19-24.
32.Shi, Y.H. and W.G. Fang, Hypoxia-inducible factor-1 in tumour angiogenesis. World journal of gastroenterology, 2004; 10(8): p. 1082-7.
33.Masoud, G.N. and W. Li, HIF-1alpha pathway: role, regulation and intervention for cancer therapy. Acta pharmaceutica Sinica. B, 2015; 5(5): p. 378-89.
34.Knowles, H.J., et al., Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer research, 2003; 63(8): p. 1764-8.
35.Shin, D.H., et al., Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood, 2008;111(6): p. 3131-6.
36.Lee, Y.M., et al., Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha. Carcinogenesis, 2009; 30(10): p. 1768-75.
37.Kong D, P.E., Stephen AG., Echinomycin, a smallmolecule inhibitor of hypoxia-inducible factor-1 DNA binding activity. . Cancer Res., 2005;65: p. 9047-9055.
38.Isaacs, J.S., et al., Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. The Journal of biological chemistry, 2002. 277(33): p. 29936-44.
39.Ricker, J.L., et al., 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004;10(24): p. 8665-73.
40.Yeo, E.J., et al., YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. Journal of the National Cancer Institute, 2003; 95(7): p. 516-25.
41.Rapisarda A, U.B., Sordet O., Topoisomerase I-mediated inhibition of hypoxiainducible factor 1: mechanism and therapeutic implications. . Cancer Res., 2004; 64: p. 1475-1482.
42.Zhang, H., et al., Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2008; 105(50): p. 19579-86.
43.Koh, M.Y., et al., Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Molecular cancer therapeutics, 2008; 7(1): p. 90-100.
44.Hudson, C.C., et al., Regulation of hypoxia-inducible factor 1alpha expression and function by

the mammalian target of rapamycin. Molecular and cellular biology, 2002; 22(20): p. 7004-14.
45. Lee YM, L.J., Yoon H, Chun YS, Park JW., Antihepatoma activity of chaetocin due to deregulated splicing of hypoxia-inducible factor 1α pre-mRNA in mice and in vitro. Hepatology, 2011. 53: p. 171-180.
46.Jensen, R.L., et al., Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. Journal of neuro-oncology, 2006;78(3): p. 233-47.
47.Sun, X., et al., Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene therapy, 2001;8(8): p. 638-45.
48.Chang Q, Q.R., Huang T, Gao J, Feng Y. , Effect of antisense hypoxia-inducible factor 1alpha on progression, metastasis, and chemosensitivity of pancreatic cancer. . Pancreas., 2006; 32: p. 297-305.